Cochrane · systematic review · CD006363
Regular treatment with salmeterol for chronic asthma: serious adverse events
Cates, CJ, Cates, MJ · Cochrane Database of Systematic Reviews · 2008 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
13
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 7.1%Very low 0 · 0%Low 4 · 28.6%Moderate 7 · 50%High 2 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Regular salmeterol compared to placebo for chronic asthma
Population: patients with chronic asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality ‐ adults and adolescents Regular salmeterol vs placebo | OR 1.33 [0.85, 2.08] | 10 studies · 29128 participants | Moderate Downgraded: imprecision |
All‐cause mortality ‐ children Regular salmeterol vs placebo | no estimate extracted | 4 studies · 1126 participants | Ungraded |
All‐cause non‐fatal serious adverse events ‐ adults and adolescents Regular salmeterol vs placebo | OR 1.14 [1.01, 1.28] | 13 studies · 30196 participants | High |
All‐cause non‐fatal serious adverse events ‐ children Regular salmeterol vs placebo | OR 1.3 [0.82, 2.05] | 5 studies · 1333 participants | Moderate Downgraded: imprecision |
Asthma‐related mortality ‐ adults and adolescents Regular salmeterol vs placebo | OR 3.49 [1.31, 9.31] | 10 studies · 29128 participants | High |
Asthma‐related non‐fatal serious adverse events ‐ adults and adolescents Regular salmeterol vs placebo | OR 1.43 [0.75, 2.71] | 12 studies · 3841 participants | Low Downgraded: imprecision |
Asthma‐related non‐fatal serious adverse events ‐ children Regular salmeterol vs placebo | OR 1.72 [1, 2.98] | 5 studies · 1333 participants | Moderate |
Regular salmeterol compared to regular salbutamol for chronic asthma
Population: patients with chronic asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality ‐ adults and adolescents Regular salmeterol vs regular salbutamol | OR 1.28 [0.79, 2.05] | 4 studies · 26463 participants | Moderate Downgraded: imprecision |
All‐cause mortality ‐ children Regular salmeterol vs regular salbutamol | OR 0.04 [0, 2.97] | 3 studies · 1152 participants | Low Downgraded: imprecision |
All‐cause non‐fatal serious adverse events ‐ adults and adolescents Regular salmeterol vs regular salbutamol | OR 0.96 [0.85, 1.1] | 5 studies · 27002 participants | Moderate |
All‐cause non‐fatal serious adverse events ‐ children Regular salmeterol vs regular salbutamol | OR 1.37 [0.71, 2.64] | 3 studies · 1181 participants | Moderate Downgraded: imprecision |
Asthma‐related mortality ‐ adults and adolescents Regular salmeterol vs regular salbutamol | OR 2.36 [0.78, 7.16] | 4 studies · 26463 participants | Moderate Downgraded: imprecision |
Asthma‐related non‐fatal serious adverse events ‐ adults and adolescents Regular salmeterol vs regular salbutamol | OR 0.94 [0.37, 2.34] | 3 studies · 1155 participants | Low Downgraded: imprecision |
Asthma‐related non‐fatal serious adverse events ‐ children Regular salmeterol vs regular salbutamol | OR 1.04 [0.47, 2.31] | 3 studies · 1186 participants | Low Downgraded: imprecision |